Core-Shell Magnetoelectric Nanocomposites for Targeted Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing magnetoelectric nanocomposites face challenges in achieving high specificity, bioavailability, and controlled drug release for targeted drug delivery, particularly in treating colorectal cancer.
Innovation Solution
Development of rare earth metal doped spinel ferrite nanoparticles coated with a ferroelectric compound, such as barium titanate, forming a core-shell magnetoelectric nanocomposite with specific properties for targeted drug delivery and enhanced biocompatibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional magnetoelectric nanocomposites are used for drug delivery, then magnetic targeting capability is achieved, but specificity and controlled drug release remain compromised
Solution Approach 1:
The patent creates a core-shell nanocomposite structure where the core contains magnetoelectric materials (ferromagnetic Fe3O4 and ferroelectric Pb(Zr,Ti)O3) and the shell contains biocompatible polymers (chitosan and gelatin). This composite structure integrates multiple functional materials to achieve magnetic targeting, electric field-responsive drug release, and biocompatibility simultaneously, resolving the contradiction between reliability and device complexity.
Solution Approach 2:
The nanocomposite employs a nested structure where Fe3O4 nanoparticles are embedded within Pb(Zr,Ti)O3 matrix, and this core is further encapsulated by chitosan and gelatin shell layers. This nested architecture allows each material to contribute its specific function while maintaining overall system integrity, achieving high specificity without excessive structural complexity.
2Reliability
If magnetoelectric nanocomposites are designed for targeted delivery, then localization capability is improved, but bioavailability and controlled release are compromised
Solution Approach 1:
The patent utilizes the magnetoelectric effect to change the physical parameters of the nanocomposite shell. By applying an external electric field, the ferroelectric Pb(Zr,Ti)O3 component undergoes polarization changes that modify the shell's permeability and structure, enabling controlled drug release. This parameter change approach maintains high bioavailability while achieving precise control over drug delivery timing and rate.
Solution Approach 2:
The biocompatible polymer shell (chitosan and gelatin) acts as an intermediary between the magnetoelectric core and the biological environment. This intermediary layer protects the core materials from premature degradation, enhances bioavailability, and simultaneously serves as the controlled release mechanism through electric field-induced changes in polymer conformation and permeability.
3Strength
If rare earth metal doping is applied to spinel ferrite, then magnetic properties are enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent incorporates rare earth metals (such as Nd, Dy, or Tb) into the spinel ferrite structure during the initial sol-gel synthesis process rather than attempting post-synthesis doping. The rare earth metal salts are mixed with iron salts and organic precursors before gel formation, ensuring uniform distribution and simplifying the manufacturing process while achieving enhanced magnetic properties through the preliminary incorporation of dopant elements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanocomposite demonstrates selective targeting and significant reduction in colorectal cancer cell viability, with minimal toxicity to normal cells, achieving over 10% decrease in cancer cell viability and effective drug delivery.
Implementation Method 1
MENs are a combination of ferroelectric and ferromagnetic phases that provide magnetoelectric (ME) duality and functionality
Implementation Method 2
the ferroelectric compound is barium titanate (BTO)
Data Source
AI summary
A magnetoelectric nanocomposite (MEN) is described. The MEN are used as a colorectal cancer treatment. The MEN includes a shell having at least one ferroelectric compound and a rare earth (R) metal doped spinel ferrite nanoparticle (SFNP) core, of a formula of CoxMn1-xR2-yFeyOz wherein x=0.1-0.9, y=1.90-1.99, and z=3-5; and R is at least one rare earth metal selected from the group consisting of cerium (Ce), europium (Eu), gadolinium (Gd), terbium (Tb) and thulium (Tm). A method of making MENs is also provided.